What question did this study set out to answer?

Evaluate the safety and efficacy of CK0804 T regulatory cells in myelofibrosis patients receiving ruxolitinib.

December 8, 2025BloodOpen Access

Dose intensive regimen of CK0804 tregs in myelofibrosis

View Full Paper

Ask AI

Bookmark

Authors

LMLucia MasárováThe University of Texas MD Anderson Cancer Center TKTapan KadiaThe University of Texas MD Anderson Cancer Center GMGuillermo Montalban‐BravoThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Clinical trial reports decreased symptom burden in myelofibrosis with CK0804 T regulatory cells added to ruxolitinib, indicating potential for improved treatment efficacy.

Key Points

Evaluate the safety and efficacy of CK0804 T regulatory cells in myelofibrosis patients receiving ruxolitinib.
Conducted a clinical trial with an expansion cohort for dose intensive CK0804 Tregs.
Patients received 4 weekly infusions followed by 5 monthly infusions of CK0804 Tregs.
Safety and overall response was evaluated at 24 weeks per IWG-MRT criteria.
No grade 3-4 treatment related adverse events were reported during the trial.
62.5% of patients saw a decrease in at least 2 disease measures after 12 months.
Responders experienced an average 49% decrease in symptom burden, while non-responders experienced a 169% increase.

Cite This Study

Masárová et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236df85 https://doi.org/10.1182/blood-2025-5602

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial reports decreased symptom burden in myelofibrosis with CK0804 T regulatory cells added to ruxolitinib, indicating potential for improved treatment efficacy.

Dose intensive regimen of CK0804 tregs in myelofibrosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Dose intensive regimen of CK0804 tregs in myelofibrosis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider